Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19
Unknown authors
Abstract
This Medical Letter review summarizes the use of tixagevimab and cilgavimab (Evusheld), investigational long-acting monoclonal antibodies to be administered concomitantly by intramuscular injection for preexposure prophylaxis of COVID-19 in persons aged 12 years or older.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus InfectionsMonoclonal antibodyBetacoronavirusVirologyIntensive care medicineAntibodyInternal medicineImmunologyOutbreakInfectious disease (medical specialty)DiseaseIntramuscular injections and effectsSARS-CoV-2 and COVID-19 ResearchPharmaceutical studies and practices